Antibe Therapeutics Inc.
ATE
株式のランク
#31892
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
株価
$0.21483059
最終同期: 2024-05-07
時価総額
$11.13M
変化（1日）
0.34%
変化（1年）
-0.36%
国
CA
取引 Antibe Therapeutics Inc. (ATE)
カテゴリー
Healthcare
Antibe Therapeutics Inc.（ATE）のP/S比率
2026 時点のP/S比率 TTM: 0
Antibe Therapeutics Inc. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
Antibe Therapeutics Inc. の P/S 比率の履歴（2026 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 3.82 | - |
US
|
|
| 2.78 | - |
IE
|
|
| 4.18 | - |
US
|
|
| 2.97 | - |
US
|
|
| - | - |
DE
|
